LY2835219 free base - CAS# 1231929-97-7 size:2mg solid Pre-treatment of cells prior to

Pre-treatment of cells prior to stimulation with GM-CSF and the DMSO control with the PI3K inhibitors Wortmannin (50 nM)

Treatment with 5 μM ROC-325 for 24 hours leads to the formation of LC3B punctae and a robust increase in LC3B levels in both A498 and 786-0 RCC cells

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo

CAS Number: 1020719-62-3

or 50 μM) has no effect on cell viability

LY2835219 free base - CAS# 1231929-97-7 size:2mg solid Pre-treatment of cells prior toLY2835219 free base, CAS No. 1231929 97 7, is orally available cyclin dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK mediated